☰

Sadhna Joshi - Publications

Affiliations: 
University of Toronto, Toronto, ON, Canada 
Area:
Microbiology Biology, Molecular Biology, Mental Health
Tree Info Similar researchers PubMed Report error

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Falkenhagen A, Joshi S. Genetic Strategies for HIV Treatment and Prevention. Molecular Therapy. Nucleic Acids. 13: 514-533. PMID 30388625 DOI: 10.1016/J.Omtn.2018.09.018  0.583
2018 Falkenhagen A, Joshi S. HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins. Molecular Therapy. Nucleic Acids. 13: 347-364. PMID 30340139 DOI: 10.1016/J.Omtn.2018.09.003  0.544
2017 Falkenhagen A, Singh J, Asad S, Leontyev D, Read S, Zúñiga-Pflücker JC, Joshi S. Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor. Molecular Therapy. Nucleic Acids. 9: 132-144. PMID 29246292 DOI: 10.1016/J.Omtn.2017.08.017  0.58
2017 Falkenhagen A, Joshi S. Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45. Molecular Therapy. Nucleic Acids. 7: 387-395. PMID 28624214 DOI: 10.1016/J.Omtn.2017.04.017  0.57
2016 Falkenhagen A, Asad S, Read SE, Joshi S. Lentiviral expression system for the purification of secreted proteins from human cell cultures. Bmc Biotechnology. 16: 66. PMID 27590008 DOI: 10.1186/S12896-016-0288-3  0.325
2016 Landry I, Zhu L, Abutarif M, Hruska M, Sadler BM, Pitsiu M, Joshi S, Hanna GJ, Lataillade M, Boulton DW, Bertz RJ. Model-based Phase 3 dose selection for HIV-1 attachment inhibitor prodrug BMS-663068 in HIV-1-infected patients: population pharmacokinetics/pharmacodynamics of the active moiety, BMS-626529. Antimicrobial Agents and Chemotherapy. PMID 26902761 DOI: 10.1128/AAC.02503-15  0.389
2014 Falkenhagen A, Ameli M, Asad S, Read SE, Joshi S. A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells. Gene Therapy. 21: 175-87. PMID 24305417 DOI: 10.1038/Gt.2013.70  0.516
2013 Falkenhagen A, Ameli M, Asad S, Read SE, Joshi S. Gene therapy using a secreted single chain variable fragment targeting CCR5 to inhibit HIV infection Journal of Antivirals and Antiretrovirals. 5: 85-91. DOI: 10.4172/Jaa.1000069  0.607
2010 LEE-RUFF E, OSTROWSKI M, LADHA A, STYNES DV, VERNIK I, JIANG J, WAN W, DING S, JOSHI S. ChemInform Abstract: Synthesis and HIV Inhibition Activity of 2′,3′-Dideoxy-3′-C-hydroxymethyl Nucleosides. Cheminform. 28: no-no. DOI: 10.1002/CHIN.199716252  0.361
2009 Nazari R, Joshi S. HIV-1 gene therapy at pre-integration and provirus DNA levels. Current Gene Therapy. 9: 20-5. PMID 19275568 DOI: 10.2174/156652309787354658  0.537
2008 Nazari R, Joshi S. Exploring the potential of group II introns to inactivate human immunodeficiency virus type 1. The Journal of General Virology. 89: 2605-10. PMID 18796730 DOI: 10.1099/Vir.0.2008/004333-0  0.62
2008 Nazari R, Ma XZ, Joshi S. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA. The Journal of General Virology. 89: 2252-61. PMID 18753234 DOI: 10.1099/Vir.0.2008/001222-0  0.625
2008 Nazari R, Joshi S. CCR5 as target for HIV-1 gene therapy. Current Gene Therapy. 8: 264-72. PMID 18691022 DOI: 10.2174/156652308785160674  0.556
2006 Ramezani A, Ma XZ, Ameli M, Arora A, Joshi S. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes. Frontiers in Bioscience : a Journal and Virtual Library. 11: 2940-8. PMID 16720366 DOI: 10.2741/2023  0.739
2002 Ramezani A, Ma XZ, Nazari R, Joshi S. Development and testing of retroviral vectors expressing multimeric hammerhead ribozymes targeted against all major clades of HIV-1. Frontiers in Bioscience : a Journal and Virtual Library. 7: a29-36. PMID 11815297 DOI: 10.2741/Ramezani  0.75
2002 Ding SF, Lombardi R, Nazari R, Joshi S. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins. Frontiers in Bioscience : a Journal and Virtual Library. 7: a15-28. PMID 11815282 DOI: 10.2741/Ding  0.667
2000 Singwi S, Joshi S. Potential nuclease-based strategies for HIV gene therapy. Frontiers in Bioscience : a Journal and Virtual Library. 5: D556-79. PMID 10799357 DOI: 10.2741/Singwi  0.625
2000 Lamothe B, Joshi S. Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies. Frontiers in Bioscience : a Journal and Virtual Library. 5: D527-55. PMID 10799355 DOI: 10.2741/Lamothe  0.683
1999 Medina MF, Joshi S. RNA-polymerase III-driven expression cassettes in human gene therapy. Current Opinion in Molecular Therapeutics. 1: 580-94. PMID 11249665  0.648
1999 Singwi S, Ramezani A, Ding SF, Joshi S. Targeted RNases: a feasibility study for use in HIV gene therapy. Gene Therapy. 6: 913-21. PMID 10505117 DOI: 10.1038/Sj.Gt.3300884  0.732
1999 Medina MF, Joshi S. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes. Nucleic Acids Research. 27: 1698-708. PMID 10076002 DOI: 10.1093/Nar/27.7.1698  0.738
1998 Ding SF, Noronha J, Joshi S. Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication. Nucleic Acids Research. 26: 3270-8. PMID 9628929 DOI: 10.1093/Nar/26.13.3270  0.643
1997 Ramezani A, Ding SF, Joshi S. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Therapy. 4: 861-7. PMID 9338016 DOI: 10.1038/sj.gt.3300474  0.709
1997 Joshi S, Ding SF, Liem SE. Co-packaging of non-vector RNAs generates replication-defective retroviral vector particles: a novel approach for blocking retrovirus replication. Nucleic Acids Research. 25: 3199-203. PMID 9241231 DOI: 10.1093/Nar/25.16.3199  0.474
1997 Ramezani A, Marhin W, Weerasinghe M, Joshi S. A rapid and efficient system for screening HIV-1 Pol mRNA-specific ribozymes. Canadian Journal of Microbiology. 43: 92-6. PMID 9057298 DOI: 10.1139/M97-013  0.705
1996 Joshi S, Joshi RL. Molecular biology of human immunodeficiency virus Type-1 Transfusion Science. 17: 351-378. PMID 10163543 DOI: 10.1016/0955-3886(96)00004-5  0.471
1996 Ramezani A, Joshi S. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo. Antisense & Nucleic Acid Drug Development. 6: 229-35. PMID 8915508 DOI: 10.1089/Oli.1.1996.6.229  0.73
1996 Melekhovets YF, Joshi S. Fusion With an RNA Binding Domain to Confer Target RNA Specificity to an RNase: Design and Engineering of Tat-RNase H That Specifically Recognizes and Cleaves HIV-1 RNA in vitro Nucleic Acids Research. 24: 1908-1912. PMID 8657573 DOI: 10.1093/Nar/24.10.1908  0.575
1996 Medina M, Ramezani A, Joshi S. Anti-HIV-1 gene therapy Transfusion Science. 17: 109-120. DOI: 10.1016/0955-3886(95)00064-X  0.528
1996 Ramezani A, Noronha J, Tsoi V, Zhang C, Asad S, Read S, Ngan B, Joshi S. A simple SCID mouse model for HIV research Transfusion Science. 17: 99-108. DOI: 10.1016/0955-3886(95)00063-1  0.514
1994 Cohli H, Fan B, Joshi RL, Ramezani A, Li X, Joshi S. Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s). Antisense Research and Development. 4: 19-26. PMID 7914762 DOI: 10.1089/Ard.1994.4.19  0.722
1994 Chia W, Nisbet-Brown E, Li X, Salit I, Joshi S, Read SE. Lack of correlation between phenotype activation markers of CD8 lymphocytes and Cytotoxic T Lymphocyte (CTL) function in HIV-1 infection: evidence for rescue with rIL-2 Viral Immunology. 7: 81-95. PMID 7848511 DOI: 10.1089/Vim.1994.7.81  0.519
1993 Liem SE, Ramezani A, Li X, Joshi S. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Human Gene Therapy. 4: 625-34. PMID 8280800 DOI: 10.1089/Hum.1993.4.5-625  0.689
1991 Weerasinghe M, Liem SE, Asad S, Read SE, Joshi S. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. Journal of Virology. 65: 5531-4. PMID 1895402 DOI: 10.1128/Jvi.65.10.5531-5534.1991  0.654
1991 Joshi S, Van Brunschot A, Asad S, van der Elst I, Read SE, Bernstein A. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. Journal of Virology. 65: 5524-30. PMID 1895401 DOI: 10.1128/Jvi.65.10.5524-5530.1991  0.669
1990 Joshi S, Van Brunschot A, Robson I, Bernstein A. Efficient replication, integration, and packaging of retroviral vectors with modified long terminal repeats containing the packaging signal. Nucleic Acids Research. 18: 4223-6. PMID 2377461 DOI: 10.1093/Nar/18.14.4223  0.396
Show low-probability matches.